Table 5.
Clinical predictors of CINV identified in the study population (nall = 710, nHEC = 139, nAC-based = 361, nXELOX = 210)
| Risk factor | Variation in patients with regards to complete response (CR) (% variation, eigenvector) | Variation in patients with regards to complete protection (CP) (% variation, eigenvector) | Variation in patients with regards to complete control (CC) (% variation, eigenvector) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Acute | Delayed | Overall | Acute | Delayed | Overall | Acute | Delayed | Overall | |
| Ex-/current drinkers | |||||||||
| All | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| HEC | -- | 20.8% of PC1, 0.421/ -0.421 | 20.6% of PC1, -0.405/ 0.405 | -- | 22.9% of PC1, 0.411/ -0.411 | 23.0% of PC1, 0.399/ -0.399 | -- | 25.0% of PC1, -0.423/ 0.423* | 26.0% of PC1, -0.411/ 0.411* |
| AC-based | -- | -- | -- | 11.8% of PC3, 0.538/ -0.538 | -- | -- | 12.3% of PC3, 0.592/ -0.592 | -- | -- |
| XELOX | 13.7% of PC2, 0.543/ -0.543 | -- | -- | -- | -- | -- | -- | -- | -- |
| Social/chronic drinkers | |||||||||
| All | 9.6% of PC4, -0.408/ 0.408 | -- | -- | -- | -- | -- | -- | -- | -- |
| HEC | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| AC-based | 17.3% of PC1, 0.535/ -0.535* | -- | -- | -- | -- | -- | -- | -- | -- |
| XELOX | -- | 17.4% of PC1, 0.458/ -0.458 | 17.6% of PC1, 0.459/ -0.459 | 18.0% of PC1, -0.426/ 0.426 | -- | -- | -- | -- | -- |
| Non-drinkers | |||||||||
| All | -- | -- | -- | -- | 6.2% of PC6, 0.534 | 6.1% of PC6, 0.588 | -- | -- | -- |
| HEC | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| AC-based | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| XELOX | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Fatigue interference | |||||||||
| All | 11.7% of PC3, 0.440 | 10.7% of PC4, 0.389 | 10.2% of PC4, 0.484 | 10.3% of PC4, 0.495 | 9.3% of PC4, 0.379 | -- | 9.7% of PC4, 0.438 | -- | -- |
| HEC | -- | -- | -- | 10.3% of PC5, 0.512 | 10.3% of PC4, 0.508 | -- | -- | 12.5% of PC3, 0.481 | 11.8% of PC3, 0.477 |
| AC-based | 5.8% of PC8, -0.449 | -- | -- | -- | -- | -- | 13.4% of PC2, 0.438 | -- | -- |
| XELOX | -- | -- | 13.9% of PC3, 0.454 | -- | 12.2% of PC3, 0.447 | 13.4% of PC3, 0.486 | 14.9% of PC2, 0.472 | -- | -- |
| Fatigue severity | |||||||||
| All | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| HEC | -- | 5.7% of PC7, 0.547 | -- | -- | -- | -- | 5.4% of PC8, -0.400 | 5.9% of PC8, -0.297 | 10.3% of PC4, 0.456 |
| AC-based | -- | -- | -- | -- | -- | 9.2% of PC4, 0.367 | -- | 9.8% of PC4, 0.451 | 9.8% of PC4, 0.411 |
| XELOX | -- | -- | -- | 12.9% of PC3, 0.436 | -- | -- | -- | -- | -- |
| Gender | |||||||||
| All | 17.7% of PC1, 0.476 | 17.3% of PC1, 0.482 | -- | 17.6% of PC1, 0.449 | -- | -- | 16.2% of PC1, 0.499 | -- | -- |
| HEC | -- | -- | 10.7% of PC4, 0.461 | 11.1% of PC4, 0.551 | -- | -- | 11.4% of PC4, 0.548 | 9.8% of PC5, 0.455 | -- |
| AC-based | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| XELOX | -- | 11.9% of PC4, 0.477 | -- | -- | -- | -- | -- | 11.3% of PC3, 0.409 | -- |
| History of chemotherapy-induced nausea | |||||||||
| All | -- | -- | -- | -- | -- | 7.4% of PC5, 0.434 | 7.2% of PC5, 0.479 | -- | -- |
| HEC | -- | -- | -- | -- | 4.3% of PC9, 0.427 | 4.6% of PC9, 0.549 | -- | 4.9% of PC9, 0.483 | 5.0% of PC9, 0.442 |
| AC-based | -- | -- | -- | 12.7% of PC3, 0.444 | 13.2% of PC3, 0.456 | -- | -- | 12.9% of PC2, 0.430 | -- |
| XELOX | -- | 16.5% of PC2, 0.427 | 17.0% of PC2, 0.433 | 8.3% of PC5, 0.547 | -- | -- | -- | -- | -- |
| History of chemotherapy-induced vomiting | |||||||||
| All | -- | -- | -- | -- | -- | -- | -- | -- | 4.5% of PC10, -0.386 |
| HEC | -- | 21.6% of PC1, 0.453 | 20.5% of PC1, 0.465 | -- | 20.8% of PC1, 0.449 | -- | -- | 19.2% of PC1, 0.46 | -- |
| AC-based | -- | -- | -- | -- | 4.9% of PC10, 0.436 | -- | 12.8% of PC3, 0.442 | 4.7% of PC10, 0.445 | -- |
| XELOX | -- | -- | -- | 7.9% of PC6, 0.598 | -- | -- | -- | -- | -- |
All: All regimens inclusive of HEC, AC-based and XELOX regimens.
HEC: Highly-emetogenic regimens (CDDP40, CDDP100 and PF regimens).
AC-based: AC-based regimens (AC, FAC and FEC regimens).
XELOX: XELOX regimen.
*Direction cosine is greater than 0.71, therefore the risk factor is closely related to its principal component.